A retrospective analysis of 11 dogs with surface osteosarcoma

Vet Comp Oncol. 2022 Mar;20(1):82-90. doi: 10.1111/vco.12741. Epub 2021 Jun 20.

Abstract

While the majority of canine osteosarcomas (OSA) arise from the medullary cavity, a subset arises from the surface of bone. In humans, surface OSA often has a more indolent disease course with better outcomes than medullary OSA. The aim of this retrospective case series was to evaluate the clinical outcome and potential prognostic factors of dogs with surface OSA. Medical records from 11 dogs previously diagnosed with surface OSA were included. Histopathology of cases was evaluated during case review by two veterinary anatomic pathologists. Median progression free interval (PFI) and overall median survival time (OST) were estimated using Kaplan-Meier methods. Intergroup comparisons were performed using log-rank tests. Six dogs were diagnosed with periosteal OSA, 4 dogs with parosteal OSA, and one dog with an unclassified surface OSA. Two dogs were found to have metastatic disease at the time of diagnosis and four developed metastatic lesions after treatment. The median PFI and median OST for all dogs with surface OSA was 425 and 555 days, respectively. The 6 dogs diagnosed with periosteal OSA had a median PFI of 461 days and median OST of 555 days, while the 4 dogs with parosteal OSA had a PFI of 350 days and the OST could not be calculated. Multiple prognostic factors (surgery, systemic adjunctive therapy, elevated alkaline phosphatase at diagnosis, appendicular vs axial location, mitotic count, and tumour grade) were evaluated and none were prognostic for PFI or OST. Dogs with surface OSA appear to have prolonged PFI and OST, consistent with humans with surface OSA.

Keywords: oncology; pathology; small animal; surgical oncology; tumor biology.

MeSH terms

  • Animals
  • Bone Neoplasms* / diagnosis
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / veterinary
  • Dog Diseases* / pathology
  • Dogs
  • Osteosarcoma* / diagnosis
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / veterinary
  • Retrospective Studies